Abstract

Objective: to compare the clinical efficacy of complex therapy, including a combination of a nonsteroidal anti-inflammatory drug (NSAID) with a muscle relaxant and B vitamins in acute musculoskeletal back pain (MSBP). Patients and methods. We enrolled 66 patients with acute MSBP, 27 men and 39 women, mean age – 52.8 [29.4; 68.8] years. All patients had different pain localization: 36 (54.5%) – lumbodynia, 22 (33.3%) – cervicodynia, 8 (12.2%) – thoracodynia. Visual analog scale (VAS) was used to assess pain intensity. Patients in the 1 st group (n=32) were prescribed with complex therapy, including Russian drugs meloxicam (Amelotex 15 mg per day), tolperison (Kalmirex), and a neurotropic multivitamin supplement Compligam B. Patients in the 2 nd group (n=34) received a combination of only two of the three drugs. We assessed pain intensity with VAS, disability duration, and treatment effectiveness from the doctor's and patient's perspectives. Results and discussion. After 5 days of treatment, pain regression was noted in both groups; pain reduction by 50% or more from the initial level prevailed in 1 st group (p=0.03). A rapid NSAID dose decrease prevailed in the 1 st group; from the 5 th to the 10 th day, all patients switched to the 7.5 mg meloxicam dose. The duration of temporary disability in the 1 st group was less than 7 days, in the 2 nd group – 9 days (p<0.05). Complex therapy in group 1 was more effective than therapy in group 2, according to doctors and patients (p<0.05). Conclusion . The combination of NSAID with a muscle relaxant and B vitamins can reduce the duration and the incidence of adverse drug reactions of NSAID therapy, and reduce the duration of temporary disability.

Highlights

  • Pain reliever combinations in treatment of patients with acute musculoskeletal back pain Gorenkov R.V.1, 2, Dadasheva M.N.3, Lebedeva D.I.4, Choi I.V.5

  • After 5 days of treatment, pain regression was noted in both groups; pain reduction by 50% or more from the initial level prevailed in 1st group (p=0.03)

  • A rapid nonsteroidal anti-inflammatory drug (NSAID) dose decrease prevailed in the 1st group; from the 5th to the 10th day, all patients switched to the 7.5 mg meloxicam dose

Read more

Summary

ОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯ И МЕТОДИКИ

Горенков Р.В.1, 2, Дадашева М.Н.3, Лебедева Д.И.4, Цой И.В.5 1ФГБНУ «Национальный научно-исследовательский институт общественного здоровья им. Цель исследования – сравнение клинической эффективности комплексной терапии, включающей комбинацию нестероидного противовоспалительного препарата (НПВП) с миорелаксантом и витаминами группы В, при острой скелетно-мышечной боли в спине (СМБС). В процессе исследования оценивали интенсивность боли по ВАШ, продолжительность нетрудоспособности, эффективность лечения по мнению пациентов и врачей. Комбинация НПВП с миорелаксантом и витаминами группы В позволяет уменьшить длительность терапии НПВП и снизить частоту осложнений от их приема, сократить продолжительность временной нетрудоспособности. Medical University, Ministry of Health of Russia, Tyumen; 5Central Clinical Hospital of the Russian Academy of Sciences, Moscow 112, Vorontsovo Pole St., Build. Objective: to compare the clinical efficacy of complex therapy, including a combination of a nonsteroidal anti-inflammatory drug (NSAID) with a muscle relaxant and B vitamins in acute musculoskeletal back pain (MSBP). We assessed pain intensity with VAS, disability duration, and treatment effectiveness from the doctor's and patient's perspectives

Results and discussion
Длительность болевого синдрома
НПВП и вследствие этого избежать
Число оценивших
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.